Vertex Pharmaceuticals Incorporated
Loading chart...
1
PART I
ITEM 1.BUSINESS
OVERVIEW
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for
people with serious diseases, with a focus on specialty markets. We have approved medicines for cystic fibrosis (“CF”),
sickle cell disease (“SCD”), transfusion dependent beta thalassemia (“TDT”), and acute pain, and we continue to serially
innovate and advance next-generation clinical and research programs in these areas. Our mid- and late-stage clinical pipeline
includes programs across a range of modalities in additional serious diseases, including IgA nephropathy, APOL1-mediated
kidney disease, neuropathic pain, type 1 diabetes, primary membranous nephropathy, autosomal dominant polycystic kidney
disease, and myotonic dystrophy type 1.
The following chart sets forth our approved products, clinical-stage programs, and select pre-clinical programs:
We are advancing five pivotal programs across multiple disease areas:
•IgA Nephropathy. We are developing povetacicept, a dual inhibitor of the B cell activating factor (“BAFF”) and a
proliferation-inducing ligand (“APRIL”) pathways, as a potentially best-in-class approach to treat IgA nephropathy
(“IgAN”), a serious, progressive, life-threatening kidney disease that often progresses to end-stage renal disease. We
completed enrollment in the IgAN Phase 3 clinical trial and submitted the first module of the rolling Biologics
Licensing Application (“BLA”) for povetacicept in IgAN in the fourth quarter of 2025. We expect to complete the
submission for potential accelerated approval in the U.S. in the first half of 2026.
•APOL1-Mediated Kidney Disease. We are developing inaxaplin, a small molecule inhibitor of APOL1 as a potential
first-in-class treatment for APOL1-mediated kidney disease (“AMKD”). We have completed the enrollment of the
interim analysis cohort of the Phase 2/3 clinical trial and will conduct the pre-planned interim analysis once this
cohort reaches 48 weeks of treatment. We expect to share data from the interim analysis in late 2026 or early 2027.
•Peripheral Neuropathic Pain. We are developing suzetrigine, a selective non-opioid NaV1.8 pain signal inhibitor,
for diabetic peripheral neuropathy (“DPN”), a common form of peripheral neuropathic pain. We are evaluating
suzetrigine for the treatment of DPN in two Phase 3 clinical trials. We expect to complete enrollment in both Phase
3 clinical trials by the end of 2026.
2
•Type 1 Diabetes. Zimislecel is an allogeneic stem-cell derived, fully differentiated islet cell therapy in pivotal
development for the treatment of type 1 diabetes (“T1D”). We have completed enrollment in the Phase 1/2/3 clinical
trial of zimislecel in people with T1D. We have temporarily postponed completion of the dosing in this clinical trial,
pending an ongoing internal manufacturing analysis.
•Primary Membranous Nephropathy. We are also developing povetacicept to treat primary membranous nephropathy
(“pMN”), a rare and serious autoimmune glomerular disease that can lead to kidney damage and renal failure, and
which has no treatments specifically approved for this condition. We continue to enroll and dose patients in the
adaptive Phase 2/3 pivotal trial in people with pMN. We expect to complete the Phase 2 portion of the clinical trial
and to initiate the Phase 3 portion in mid-2026.
Our core strategy is to discover, develop, and commercialize innovative medicines by combining transformative
advances in the understanding of human disease and the science of therapeutics, to dramatically advance human health. We
focus on validated targets that address causal human biology, predictive lab assays and clinical biomarkers, rapid paths to
registration and approval, and product candidates that hold the potential for transformative patient benefit. Our approach
includes advancing multiple compounds or therapies from each program into early clinical trials to obtain patient data that
can inform selection of the most promising therapies for later stage development as well as inform our ongoing discovery and
development efforts. We aim to serially innovate in our disease areas of interest and follow our first-in-class therapies with
potential best-in-class candidates. We plan to continue investing to advance our strategy, fostering scientific innovation by
identifying additional product candidates through internal research efforts, and investing in business development
Loading financial statements...
Financial statements
data from SEC XBRL filings. Values are as-reported; restatements supersede originals. Values reported in .
| Line item |
|---|
| Period ending |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for
people with serious diseases, with a focus on specialty markets. We have eight approved medicines: five that treat the
underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, one that treats severe sickle cell disease
(“SCD”) and transfusion dependent beta thalassemia (“TDT”), life shortening inherited blood disorders, one that treats
moderate-to-severe acute pain, and one that treats acromegaly. We are also preparing for the anticipated launch of
povetacicept, a potential treatment for IgA nephropathy (“IgAN”). Our clinical-stage pipeline spans a range of programs
targeting CF, SCD, beta thalassemia, IgAN, neuropathic pain, APOL1-mediated kidney disease, primary membranous
nephropathy, congenital adrenal hyperplasia, adrenocorticotropic hormone-dependent Cushing’s syndrome, autosomal
dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1, reflecting
our commitment to addressing significant unmet medical needs globally.
Financial Highlights
Total Revenues | In the third quarter of 2026, our total revenues increased to $3.4 billion as compared to $3.1 billion in the third quarter of 2025, primarily due to continued performance of our CF therapies and growth from diversification into additional disease areas. |
Cost of Sales | Our cost of sales as a percentage of our net product revenues increased to 15.3% in the third quarter of 2026 as compared to 13.5% in the third quarter of 2025, as a result of changes in product mix and increased intangible asset amortization expense resulting from our acquisition of Crinetics Pharmaceuticals, Inc. (“Crinetics”) in the third quarter of 2026 (the “Crinetics Acquisition”), partially offset by a lower blended royalty rate for our CF medicines. |
Total R&D, AIPR&D and SG&A Expenses | Our total research and development (“R&D”), acquired in-process research and development expenses (“AIPR&D”) and selling, general and administrative (“SG&A”) expenses increased to $2.2 billion in the third quarter of 2026 as compared to $1.5 billion in the third quarter of 2025, primarily due to approximately $500.0 million of compensation and transaction expenses associated with the Crinetics Acquisition. |
Cash, Cash Equivalents and Marketable Securities | Our total cash, cash equivalents and marketable securities decreased to $9.8 billion as of September 30, 2026 as compared to $12.3 billion as of December 31, 2025 primarily due to $9.0 billion net cash used to acquire Crinetics and repurchases of our common stock pursuant to our share repurchase program, partially offset by $4.5 billion borrowed pursuant to a term loan (the “2026 Term Loan”) executed in the third quarter of 2026 and cash flows provided by our operating activities. |
Q3 2025
Q3 2026
December 31, 2025
September 30, 2026
Note: Charts above may not add due to rounding.
25
Business Updates
Marketed Products
Cystic Fibrosis
We expect that the number of people with CF taking our medicines will continue to grow through new approvals and
reimbursement agreements, treatment of younger patients, increased survival and expansion into additional geographies.
Recent progress in activities expanding our CF business is included below:
•In the third quarter of 2026, we secured reimbursement for ALYFTREK in seven additional countries, bringing the
total number of countries where ALYFTREK is reimbursed to 32.
Sickle Cell Disease and Beta Thalassemia
•In the third quarter of 2026, we recorded $99.2 million of CASGEVY product revenues, representing a 30% increase
compared to the second quarter of 2026 and a more than 400% increase compared to the third quarter of 2025.
•The U.S. Food and Drug Administration (the “FDA”) approved CASGEVY in children two years of age and older
with SCD or TDT, making it the first genetic therapy for SCD and TDT indicated for children as young as two years
of age. Since approval, multiple children have initiated treatment.
•In October, the United Arab Emirates and Kingdom of Bahrain approved CASGEVY for the treatment of children 2
years of age and older, and the United Kingdom approved CASGEVY for the treatment of children 5 years of age
and older. We have completed regulatory submissions in the Kingdom of Saudi Arabia (“Saudi Arabia”) for the
treatment of children with SCD or TDT.
Acute Pain
•In the third quarter of 2026, more than 750,000 prescriptions were filled for JOURNAVX across the hospital and
retail settings, representing a more than 40% increase compared to the second quarter of 2026 and more than four
times the 170,000 JOURNAVX prescriptions that were filled in the third quarter of 2025.
•In the third quarter of 2026, we recorded $58.3 million of JOURNAVX product revenues, representing an 18%
increase since the second quarter of 2026, and nearly tripling the $19.6 million of JOURNAVX product revenues in
the third quarter of 2025.
Acromegaly
•PALSONIFY (paltusotine) is a first-in-class, small molecule, once-daily oral somatostatin receptor type 2 agonist
approved in the U.S. for the treatment of adults with acromegaly who had an inadequate response to surgery or for
whom surgery is not an option. Acromegaly is a rare and debilitating condition caused by a benign pituitary tumor
that secretes excess growth hormone. There are an estimated 12,000 adults with acromegaly in the U.S. for whom
PALSONIFY is an option.
•We recorded $10.1 million of PALSONIFY revenue in September 2026, following the closing of the Crinetics
Acquisition on September 1, 2026.
•More than 245 million individuals have access to PALSONIFY, representing approximately 80% of U.S. covered
lives.
•An estimated 3,200 endocrinologists treat the majority of people with acromegaly in the U.S. As of the end of the
third quarter of 2026, approximately 500 of those target specialty endocrinologists are prescribing PALSONIFY.
•Among patients starting or switching therapy, PALSONIFY has the leading brand share at more than 40%.
•PALSONIFY was approved in the European Union in April 2026. We expect to begin launches in European markets
in the second half of 2027. The regulatory submission for PALSONIFY in Japan was completed in April 2026, and
the Ministry of Health, Labor and Welfare (the “MHLW”) has granted orphan drug designation in Japan.
26
Pipeline
We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a
range of modalities. Recent and anticipated progress in activities supporting these efforts is included below:
Cystic Fibrosis
•We have initiated global regulatory submissions for ALYFTREK for the treatment of children with CF two to five
years of age.
Acute and Peripheral Neuropathic Pain
•We expect to complete enrollment in both Phase 3 clinical trials evaluating suzetrigine in diabetic peripheral
neuropathy, a form of peripheral neuropathic pain, by the end of 2026 and expect to share results in mid-2027.
IgA Nephropathy and Other B Cell-Mediated Diseases
•We are developing povetacicept, a dual inhibitor of B cell activating factor (“BAFF”) and a proliferation-inducing
ligand (“APRIL”) cytokines, for multiple diseases. Povetacicept represents a potentially best-in-class approach to
control B cell activity in IgAN.
•The biologics license application for accelerated approval of povetacicept for adults with IgAN is under priority
review by the FDA, with an assigned PDUFA target action date of November 30, 2026. If approved, povetacicept
will become the first commercialized therapy in our emerging nephrology franchise.
•Povetacicept is under review for accelerated approval for adults with IgAN in Saudi Arabia, and the Saudi Food and
Drug Authority has granted Breakthrough designation to povetacicept.
•Povetacicept represents a potentially best-in-class approach to control B cell activity in primary membranous
nephropathy (“pMN”), another B cell-mediated disease. We are enrolling and dosing patients in the Phase 3 portion
of the OLYMPUS Phase 2/3 pivotal trial evaluating povetacicept in people with pMN.
APOL1-Mediated Kidney Disease
•Inaxaplin is our small molecule for the treatment of APOL1-mediated kidney disease (“AMKD”). We have
completed full enrollment in the AMPLITUDE pivotal clinical trial evaluating inaxaplin.
•We are on track to conduct the pre-planned interim analysis for potential U.S. accelerated approval once the interim
analysis cohort has been treated for 48 weeks and to share data from the interim analysis in early 2027.
Rare Endocrine Disorders
•We are developing atumelnant, a once-daily oral adrenocorticotropic hormone (“ACTH”) receptor antagonist, for
the treatment of classic congenital adrenal hyperplasia (“CAH”), which affects approximately 17,000 people in the
U.S. Classic CAH is a rare, chronic, genetic condition in which the adrenal glands are unable to make enough
cortisol. Current therapies force a choice between androgen control and steroid burden, representing a significant
unmet need.
•The Phase 3 clinical trial evaluating atumelnant in adults with CAH is a global, 32-week, randomized, double blind,
placebo-controlled trial of 150 people. Enrollment and dosing are well underway, and we expect to complete
enrollment in the trial in the first quarter of 2027. The FDA, the European Medicines Agency, and the MHLW in
Japan have granted Orphan Drug designation to atumelnant in CAH.
•Atumelnant has demonstrated therapeutic potential in people with ACTH-dependent Cushing’s syndrome, another
serious endocrine disease, which affects more than 10,000 people in the U.S. We have initiated a Phase 2/3 clinical
trial evaluating atumelnant in people with ACTH-dependent Cushing’s syndrome. The FDA has granted Orphan
Drug designation to atumelnant in ACTH-dependent Cushing’s syndrome.
Type 1 Diabetes
•We are enrolling and dosing patients in a Phase 1/2 clinical trial to evaluate the safety and efficacy of VX-017 in
people with type 1 diabetes (“T1D”). VX-017 is an allogeneic, stem cell-derived, fully differentiated islet cell
therapy designed to treat the targeted patient population with T1D regardless of blood type.
27
•Given the rapid progress of VX-017, we have decided to focus on accelerating the development of VX-017, which
has the potential to reach more people than zimislecel, which is designed for people with blood types A or A/B only.
We expect to advance VX-017 into pivotal development in 2027. The FDA has granted Fast Track designation to
VX-017.
Investment in External Innovation
•In September, we completed the Crinetics Acquisition as described below.
Our Business Environment
In the first nine months of 2026, our total product revenues came primarily from the sale of our medicines for the
treatment of CF. Our CF strategy involves continuing to develop and obtain approval and reimbursement for treatment
regimens that will provide benefits to all people with CF and increasing the number of people with CF eligible and able to
receive our medicines. Outside of CF, we continue to advance the commercialization of CASGEVY for the treatment of SCD
and TDT, and JOURNAVX for the treatment of acute pain. We added PALSONIFY for the treatment of acromegaly to our
commercial portfolio in the third quarter of 2026 through the Crinetics Acquisition, and we are preparing for a potential
launch of povetacicept for the treatment of IgAN. In addition, we are advancing our pipeline of product candidates for the
treatment of serious diseases outside of CF, SCD, TDT, acute pain, and acromegaly.
Our strategy is to combine transformative advances in the understanding of causal human biology and the science of
therapeutics to discover and develop innovative medicines. This approach includes advancing multiple compounds or
therapies from each program, spanning multiple modalities, into early clinical trials to obtain patient data that can inform
selection of the most promising therapies for later-stage development, as well as to inform discovery and development
efforts. We aim to serially innovate in our disease areas of interest and follow our first-in-class therapies with potential best-
in-class candidates to provide durable clinical and commercial success.
In pursuit of new product candidates and therapies in specialty markets, we invest in research and development. We
believe that pursuing research in diverse areas allows us to balance the risks inherent in product development and may
provide product candidates that will form our pipeline in future years. To supplement our internal research programs, we
acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic
research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our
areas of therapeutic interest and to access technologies needed to execute on our strategy.
Discovery and development of a new pharmaceutical or biological product is a difficult and lengthy process that requires
significant financial resources along with extensive technical and regulatory expertise. Across the industry, most potential
drug or biological products never progress into development, and most products that advance into development never receive
marketing approval. Our investments in product candidates are subject to considerable risks. We closely monitor our research
and development activities, and frequently evaluate our pipeline programs in light of new data and scientific, business and
commercial insights, with the objective of balancing risk and potential. This process can result in rapid changes in focus and
priorities as new information becomes available and as we gain additional understanding of our ongoing programs and
potential new programs, as well as those of our competitors. In addition, our product candidates must satisfy rigorous
standards of safety and efficacy before they can be approved for sale by regulatory authorities. Our analysis of data obtained
from nonclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could
delay, limit or prevent regulatory approval.
Our business also requires ensuring appropriate manufacturing and supply of our products. As we advance our product
candidates through clinical development toward commercialization and market and sell our approved products, we build and
maintain our supply chain and quality assurance resources. We rely on a global network of third parties, including some in
China, and our internal capabilities to manufacture and distribute our products for commercial sale and post-approval clinical
trials and to manufacture and distribute our product candidates for clinical trials. In addition to establishing supply chains for
each newly approved product, we adapt our supply chain for existing products to include additional formulations or to
increase scale of production for existing products as needed. The processes for biological and cell and genetic therapies can
be more complex than those required for small molecule drugs and require additional investments in different systems,
equipment, facilities and expertise. We are focused on ensuring the stability of the supply chains for our current products, as
well as for our pipeline programs.
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors,
such as government health programs, commercial insurance and managed health care organizations. Reimbursement for our
products, including our potential pipeline therapies, cannot be assured and may take significant periods of time to obtain. We
28
dedicate substantial management and other resources to obtain and maintain appropriate levels of reimbursement for our
products from third-party payors, including governmental organizations in the U.S. and ex-U.S. markets. In the U.S., we
work with government and commercial payors to obtain and maintain appropriate levels of reimbursement for our medicines.
In ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country or region-by-region, as
required. This is necessary for each new medicine, as well as for label expansions for our current medicines. We expect to
continue to focus significant resources to expand and maintain reimbursement for our CF medicines, CASGEVY,
JOURNAVX, PALSONIFY, and, ultimately, our pipeline therapies, in U.S. and ex-U.S. markets.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to license or acquire technologies, products, product candidates and businesses
that are aligned with our corporate and research and development strategies and complement and advance our ongoing
research and development efforts. We have acquired multiple biotechnology companies over the last several years and expect
to continue to identify and evaluate such opportunities. The accounting for an acquisition can vary significantly based on
whether we conclude the relevant transaction represents a business combination or asset acquisition.
In 2024, we acquired Alpine Immune Sciences, Inc. (“Alpine”) and its lead molecule, povetacicept, for approximately
$5.0 billion. Povetacicept, has shown potential to treat multiple diseases or conditions and become a pipeline-in-a-product.
We accounted for the Alpine transaction as an asset acquisition because povetacicept represented substantially all of the fair
value of the gross assets that we acquired. As a result, $4.4 billion of the fair value attributed to povetacicept was expensed as
AIPR&D in 2024.
In September 2026, we acquired Crinetics, a publicly traded biotechnology company focused on discovering,
developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors, for $85.00 per
share in cash, equaling a total equity value of $10.0 billion, or $9.0 billion net of cash, cash equivalents and marketable
securities acquired. We funded the acquisition with our cash and cash equivalents and marketable securities, and $4.5 billion
of proceeds from the 2026 Term Loan. We have accounted for the Crinetics Acquisition as a business combination, which
resulted in $8.1 billion of additional intangible assets, as well as other assets acquired and liabilities assumed, recorded on our
condensed consolidated balance sheet. Please refer to Note C, “Business Combination,” for further information.
Collaboration and In-Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development,
manufacture and commercialization of products, product candidates and other technologies that have the potential to
complement our ongoing research and development efforts.
We have collaboration agreements with a number of companies, including CRISPR Therapeutics AG (“CRISPR”) and
Entrada Therapeutics, Inc. (“Entrada”).
Generally, when we in-license a technology or product candidate, we make upfront payments to the collaborator, assume
the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option
payments. Most of these collaboration payments are expensed as AIPR&D because they were primarily attributable to
acquired in-process research and development for which there was no alternative future use. However, depending on many
factors, including the structure of the collaboration, the stage of development of the acquired technology, the significance of
the in-licensed product candidate to the collaborator’s operations and the other activities in which our collaborators are
engaged, the accounting for these transactions can vary significantly. We expect to continue to identify and evaluate
collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have
engaged in previously.
Acquired In-Process Research and Development Expenses
In the first nine months of 2026 and 2025, our AIPR&D included $62.5 million and $76.5 million, respectively, related
to upfront, contingent milestone, or other payments pursuant to our business development transactions, including the asset
acquisitions, collaborations, and licenses of third-party technologies described above. Please refer to Note B, “Collaboration,
License and Other Arrangements,” for further information regarding our asset acquisitions, collaborations and in-license
agreements.
29
Out-licensing Arrangements
We also have out-licensed certain development programs to collaborators who are leading the development or
commercialization of these programs, either globally or within certain geographic regions.
In January 2025 and June 2025, we entered into agreements with Zai Lab Limited (“Zai”) and Ono Pharmaceuticals Co.,
Ltd (“Ono”), respectively, for the development and commercialization of povetacicept in various Asian markets. Zai licensed
povetacicept for mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore, while Ono licensed
povetacicept for Japan and South Korea. Zai and Ono will help advance povetacicept clinical trials, and will be responsible
for obtaining marketing authorizations and commercialization activities, if povetacicept becomes an approved product, in
their licensed territories. We are eligible to receive certain future milestone payments and tiered royalties on future net sales
of povetacicept in these regions.
30
RESULTS OF OPERATIONS
Total Revenues
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
(in millions, except percentages) | |||||||||||
TRIKAFTA/KAFTRIO | $2,436.9 | $2,653.6 | (8)% | $7,288.8 | $7,740.2 | (6)% | |||||
ALYFTREK | 705.8 | 247.0 | 186% | 1,703.8 | 457.7 | 272% | |||||
Other CF product revenues (1) | 130.5 | 139.3 | (6)% | 403.5 | 488.3 | (17)% | |||||
Total CF product revenues, net | 3,273.2 | 3,039.9 | 8% | 9,396.1 | 8,686.2 | 8% | |||||
CASGEVY | 99.2 | 16.9 | 487% | 218.5 | 61.5 | 255% | |||||
JOURNAVX | 58.3 | 19.6 | 197% | 136.9 | 32.9 | 316% | |||||
PALSONIFY | 10.1 | — | ** | 10.1 | — | ** | |||||
Product revenues, net | 3,440.8 | 3,076.4 | 12% | 9,761.6 | 8,780.6 | 11% | |||||
Other revenues | — | — | ** | — | 30.7 | ** | |||||
Total revenues | $3,440.8 | $3,076.4 | 12% | $9,761.6 | $8,811.3 | 11% | |||||
(1) Include KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI. | ** Not meaningful | ||||||||||
Product Revenues, Net
In the third quarter and first nine months of 2026, our net product revenues increased 12% and 11%, as compared to the
third quarter and first nine months of 2025, respectively, primarily due to continued performance of our CF therapies and
growth from diversification into additional disease areas.
Other Revenues
Other revenues were $30.7 million in the nine months ended September 30, 2025, which included $20.6 million and
$10.0 million related to upfront payments received from our collaboration agreements with Ono Pharmaceuticals Co., Ltd.
and Zai Lab Limited, respectively, in the first half of 2025.
Total Revenues by Geographic Location
Our total revenues from the U.S. and from ex-U.S. markets were as follows:
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
(in millions, except percentages) | |||||||||||
United States | $2,169.1 | $1,976.3 | 10% | $6,001.4 | $5,488.0 | 9% | |||||
ex-U.S. | 1,271.7 | 1,100.1 | 16% | 3,760.2 | 3,323.3 | 13% | |||||
Total revenues | |||||||||||
Recent insider activity
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-11-16 | Thornberry Nancy | Director | Sell | -1,000 | $547.86 | -$547,860 |
| 2026-11-16 | Bhatia Sangeeta N. | Director | Sell | -271 | $547.86 | -$148,470 |
| 2026-11-12 | WAGNER CHARLES F JR | EVP, CO & FO | Sell | -15,286 | $547.87 | -$8,374,741 |
| 2026-11-06 | Kewalramani Reshma | CEO & President | Sell | -11,866 | $531.53 | -$6,307,135 |
Source: SEC Form 4 filings.
Next expected filings
- ~2027-02-13 10-K expected by 2027-03-05 (in 83 days)
- ~2027-05-04 10-Q expected by 2027-05-09 (in 163 days)
- ~2027-08-03 10-Q expected by 2027-08-08 (in 254 days)
- ~2027-11-02 10-Q expected by 2027-11-07 (in 345 days)
Predicted from historical filing cadence; not an SEC commitment.
Recent SEC filings
- 2026-11-03 10-Q Quarterly Report
- 2026-11-02 8-K Earnings Release; Financial Statements and Exhibits
- 2026-10-20 8-K Officer/Director Change
- 2026-09-01 8-K Officer/Director Change
- 2026-08-04 10-Q Quarterly Report
- 2026-08-03 8-K Earnings Release; Financial Statements and Exhibits
- 2026-07-07 8-K Material Agreement Entered; Regulation FD Disclosure; Other Events; Financial Statements and Exhibits
- 2026-05-13 8-K Officer/Director Change; Shareholder Vote Results
- 2026-05-13 S-8 Employee Benefit Plan Registration
- 2026-05-05 10-Q Quarterly Report
- 2026-05-04 8-K Earnings Release; Financial Statements and Exhibits
- 2026-04-29 8-K Officer/Director Change
- 2026-03-31 8-K Other Events
- 2026-02-13 10-K Annual Report
- 2026-02-12 8-K Earnings Release; Financial Statements and Exhibits